| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M209640200 |
| P8608 | Fatcat ID | release_o5nflege3vd2lpr2fsslfvcly4 |
| P3181 | OpenCitations bibliographic resource ID | 611399 |
| P698 | PubMed publication ID | 12574167 |
| P50 | author | Vimla Band | Q29840414 |
| P2093 | author name string | Hamid Band | |
| David E Wazer | |||
| Pengcheng Zhou | |||
| Navin Rao | |||
| Howard Safran | |||
| Norvin Fernandes | |||
| Thomas A DiPetrillo | |||
| Alagarsamy Lakku Reddi | |||
| Ingrid L Dodge | |||
| P2860 | cites work | The development and clinical use of trastuzumab (Herceptin). | Q34744799 |
| c-Cbl is a suppressor of the neu oncogene | Q40862177 | ||
| Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin | Q41168181 | ||
| CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein | Q41776375 | ||
| Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation | Q42800575 | ||
| Protein turnover: a CHIP programmed for proteolysis. | Q43854002 | ||
| The U box is a modified RING finger — a common domain in ubiquitination | Q57263070 | ||
| Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions | Q22010047 | ||
| The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins | Q24290709 | ||
| U box proteins as a new family of ubiquitin-protein ligases | Q24291397 | ||
| Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product | Q27860841 | ||
| Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 | Q28143497 | ||
| Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7 | Q28146026 | ||
| Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling | Q28202126 | ||
| CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation | Q28216253 | ||
| A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells | Q28289338 | ||
| The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. | Q28366332 | ||
| Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers | Q28679173 | ||
| The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation | Q29616141 | ||
| Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 | Q29617290 | ||
| Regulation of receptor tyrosine kinase signaling by endocytic trafficking | Q32029952 | ||
| Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases | Q32062433 | ||
| Molecular chaperones: the busy life of Hsp90. | Q33632311 | ||
| Hsp90 & Co. - a holding for folding | Q33632917 | ||
| A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37. | Q33830135 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity | Q33888219 | ||
| Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers | Q33888963 | ||
| Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy | Q34088024 | ||
| Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins | Q34124519 | ||
| Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu | Q34190181 | ||
| New agents in cancer clinical trials | Q34293629 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular chaperones | Q422496 |
| P304 | page(s) | 13829-37 | |
| P577 | publication date | 2003-04-18 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | ErbB2 degradation mediated by the co-chaperone protein CHIP | |
| P478 | volume | 278 |
| Q41197997 | 17AAG-induced internalisation of HER2-specific Affibody molecules |
| Q28078724 | A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging? |
| Q39943622 | A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells |
| Q37251593 | A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. |
| Q40040751 | A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. |
| Q34472013 | A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair |
| Q34430965 | A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. |
| Q35053633 | A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases |
| Q40104197 | Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context. |
| Q34616517 | Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers |
| Q51578869 | CHIP chaperones wild type p53 tumor suppressor protein. |
| Q24298589 | CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation |
| Q37021183 | CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins |
| Q55333022 | CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin. |
| Q33688445 | CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR |
| Q51580141 | CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. |
| Q24338386 | CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates |
| Q37156982 | CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation |
| Q28183470 | CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival |
| Q100750457 | CHIP-mediated CIB1 ubiquitination regulated epithelial-mesenchymal transition and tumor metastasis in lung adenocarcinoma |
| Q38285306 | CHIP: a co-chaperone for degradation by the proteasome |
| Q47222331 | Chaperone-Mediated Regulation of Choline Acetyltransferase Protein Stability and Activity by HSC/HSP70, HSP90, and p97/VCP. |
| Q24296990 | Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex |
| Q38230957 | Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome |
| Q30439237 | Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells |
| Q37596323 | Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex |
| Q40420569 | Cytoplasmic expression of c-erbB2 in non-small cell lung cancers |
| Q37684761 | DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. |
| Q28184153 | Defining the role for XAP2 in stabilization of the dioxin receptor |
| Q38173991 | Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis |
| Q36525810 | Drug discovery in the ubiquitin-proteasome system. |
| Q34349106 | E3 ubiquitin ligases in ErbB receptor quantity control |
| Q30479942 | Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. |
| Q37089778 | Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer |
| Q24320293 | Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/c70 protein and the CHIP E3 ligase |
| Q34104101 | Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy |
| Q37595601 | Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases |
| Q36062148 | Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells |
| Q33820676 | ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. |
| Q58708224 | Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7 |
| Q36621228 | Expression of carboxyl terminus of Hsp70-interacting protein (CHIP) indicates poor prognosis in human gallbladder carcinoma |
| Q33743601 | Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells |
| Q42740318 | Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation |
| Q39301423 | Flotillins as regulators of ErbB2 levels in breast cancer |
| Q28593080 | Functional regulation of FEZ1 by the U-box-type ubiquitin ligase E4B contributes to neuritogenesis |
| Q52714930 | Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. |
| Q34427505 | Geldanamycin selectively targets the nascent form of ERBB3 for degradation |
| Q42801075 | Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. |
| Q38715481 | HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients. |
| Q36429542 | HSP90: a rising star on the horizon of anticancer targets |
| Q92733696 | Heat Shock Protein 90 Chaperone Regulates the E3 Ubiquitin-Ligase Hakai Protein Stability |
| Q90080306 | Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond |
| Q36531705 | Heat shock protein 70 selectively mediates the degradation of cytosolic PrPs and restores the cytosolic PrP-induced cytotoxicity via a molecular interaction |
| Q28572341 | Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes |
| Q37189447 | Heat shock proteins regulate activation-induced proteasomal degradation of the mature phosphorylated form of protein kinase C. |
| Q50850992 | Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model. |
| Q35839875 | Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with EBNA2 |
| Q36739599 | Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoid-regulated kinase-1. |
| Q90116251 | Inactivation of carboxyl terminus of Hsc70-interacting protein prevents hypoxia-induced pulmonary arterial smooth muscle cells proliferation by reducing intracellular Ca2+ concentration |
| Q37349973 | Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer |
| Q24297095 | Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation |
| Q51418131 | Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program. |
| Q28829301 | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition |
| Q35624814 | Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance |
| Q35668831 | Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination |
| Q42155234 | Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation |
| Q54443425 | NDRG2 is highly expressed in pancreatic beta cells and involved in protection against lipotoxicity. |
| Q39189607 | PELO negatively regulates HER receptor signalling and metastasis |
| Q38159469 | Post-translational regulation of the cellular levels of DAPK. |
| Q53135719 | Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes. |
| Q34380963 | Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer |
| Q37148939 | Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer |
| Q34611621 | Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage |
| Q37024066 | Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein |
| Q27009009 | Protein homeostasis at the plasma membrane |
| Q90886367 | Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation |
| Q26853052 | Quality control and fate determination of Hsp90 client proteins |
| Q34412404 | Quality control for unfolded proteins at the plasma membrane |
| Q26853207 | RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis |
| Q58770081 | Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma |
| Q33444766 | Regulation of ErbB2 receptor status by the proteasomal DUB POH1. |
| Q34627681 | Regulation of FSP27 protein stability by AMPK and HSC70. |
| Q37453413 | Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase |
| Q41106970 | Regulation of Ubiquitin-like with Plant Homeodomain and RING Finger Domain 1 (UHRF1) Protein Stability by Heat Shock Protein 90 Chaperone Machinery |
| Q24646541 | Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes |
| Q30164012 | Regulation of the Src family kinase Lck by Hsp90 and ubiquitination |
| Q39430414 | Repair or destruction-an intimate liaison between ubiquitin ligases and molecular chaperones in proteostasis |
| Q34408829 | Role of Erbin in ErbB2-dependent breast tumor growth. |
| Q26859909 | Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases |
| Q42143312 | The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer |
| Q28511737 | The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation |
| Q31107044 | The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments |
| Q38237727 | The Mysterious Ways of ErbB2/HER2 Trafficking |
| Q33384289 | The UPS: a promising target for breast cancer treatment. |
| Q37714440 | The Ubiquitination, Disaggregation and Proteasomal Degradation Machineries in Polyglutamine Disease |
| Q39425771 | The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer |
| Q39948991 | The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells |
| Q38164901 | The role of ubiquitin ligases in cardiac disease. |
| Q51547855 | Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. |
| Q51485232 | UBXN2A regulates nicotinic receptor degradation by modulating the E3 ligase activity of CHIP. |
| Q35691563 | Ubiquitin and breast cancer |
| Q39556379 | Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells. |
| Q33831775 | Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). |
| Q34260429 | miR-764-5p promotes osteoblast differentiation through inhibition of CHIP/STUB1 expression |
| Q36782465 | p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy |
Search more.